An era is opening in which next-generation vaccines are developed in artificial intelligence (AI) labs. GC녹십자 said on the 28th that it will accelerate messenger ribonucleic acid (mRNA) Vaccine development with AI at the Mogam Institute for Biomedical Research. Once developed, an mRNA Vaccine can swiftly produce a variety of vaccines by simply swapping in the virus's genetic information.
The Mogam Institute will take part in a national research project with 4.5 billion won in support from the Ministry of Science and ICT through 2030. It will develop a platform that designs mRNA structures using AI. Korea University and Hanyang University will participate as joint research institutions.
For an mRNA therapy to be effective, an optimized sequence must be identified. AI learns complex variables and recommends sequences. A researcher inputs a sequence, and AI evaluates candidate therapeutic substances and then learns again from the experimental results.
AI is expected to reduce the period and expense of designing and repeatedly testing candidate therapeutics. Shin Hyun-jin, head of the Mogam Institute for Biomedical Research, said, "We will strengthen domestic mRNA technology competitiveness."